Reference tool — not medical advice. Thresholds, targets, and first-line agents differ by guideline body and change over time — switch the lens to compare. Clinician judgement, dosing/monitoring, contraindications, and live coverage always required. Runs entirely in your browser — no data is collected.
Sexual health selector
A respectful sexual-health reference covering MALE and FEMALE concerns (Canadian CUA/SOGC, AUA/ISSWSH, Endocrine Society). Pick the concern — erectile dysfunction, low testosterone, premature ejaculation, low desire/HSDD, vaginal dryness/GSM, or arousal/orgasm — and get first-line management with safety gates (nitrates + PDE5i, fertility + testosterone) and Canadian availability flags.
Guideline lens
Concernchoose one
Menopausal status (female concerns)choose one
Comorbidities
Medications
Contributors
Concern
Select a concern to begin
Notes
- • Sexual concerns are common and treatable — a respectful, shared-decision, biopsychosocial approach applies to all sexes. This is a clinician reference, not a substitute for individual assessment.
Suggested drug classesPer Canadian (CUA / SOGC) 2021.
Select a concern to begin.
Switch the lens to see where societies differ — e.g. testosterone-for-women (ISSWSH supportive vs Endocrine Society cautious) and the male testosterone threshold (10 vs 9.2 nmol/L).
Guidelines
- 2021Canadian (CUA / SOGC) — Canadian societies — CUA (ED 2021, testosterone 2021) + SOGC 422 series (female sexual health / GSM 2021). Canadian availability and thresholds. link
- 2021AUA / ISSWSH — North American specialty societies — AUA (ED 2018, testosterone, PE/SMSNA 2020) + ISSWSH (HSDD process-of-care 2018, systemic testosterone for women CPG 2021). More supportive of HSDD pharmacotherapy / female testosterone. link
- 2019Endocrine Society / Global Consensus — Endocrine Society (testosterone in men 2018; androgen therapy in women — cautious) + 2019 Global Consensus on testosterone for women (postmenopausal only). Higher evidence bar. link
References
- [1]CUA Erectile Dysfunction Guideline (CUAJ 2021) + AUA ED Guideline (2018). ED as a cardiovascular risk marker; PDE5i first-line; nitrate contraindication; Princeton III. link
- [2]CUA Testosterone Deficiency (CUAJ 2021) + Endocrine Society Testosterone Therapy in Men (JCEM 2018) + AUA Testosterone Deficiency (2018). Confirm on 2 morning samples + symptoms; thresholds ~10 vs 9.2 nmol/L; erythrocytosis/prostate/fertility cautions. link
- [3]AUA/SMSNA Disorders of Ejaculation Guideline (2020) + ISSM PE Guideline (2014) + EAU 2024. Behavioral + topical anesthetics + SSRIs (dapoxetine not in Canada). link
- [4]ISSWSH HSDD Process of Care (2018) + Systemic Testosterone for Women CPG (2021); 2019 Global Consensus on Testosterone for Women; ACOG PB 213; Endocrine Society (Androgen Therapy in Women). Flibanserin HC-approved; bremelanotide not in Canada; female testosterone off-label. link
- [5]AUA/SUFU/AUGS Genitourinary Syndrome of Menopause Guideline (2025) + SOGC 422b/422d (2021). Non-hormonal first; low-dose vaginal estrogen; vaginal DHEA (prasterone, Canada ~2023); ospemifene (Canada ~2021). link
- [6]Lincoff AM et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). N Engl J Med 2023;389:107–117. In hypogonadal men with, or at high risk of, cardiovascular disease, testosterone was non-inferior to placebo for major adverse cardiac events — but with higher rates of atrial fibrillation, pulmonary embolism and acute kidney injury. link